Non-invasive Liquid Biopsy Allows more Frequent Testing
Offers timely insight during cancer management process
The tumor sheds small DNA fragments of circulating tumor DNA (ctDNA). The tumor genes may mutate over time, either as the cancer grows, or the treatment suppresses the cancer. ctDNA gives an accurate, real-time picture of these cancer alterations.
The CellMax-LBx non-invasive blood test is typically less expensive than surgically-obtained tissue biopsies, and is more comfortable — which is especially important given the stress that cancer and associated treatments already place on patients. The liquid biopsy also overcomes problems of inherent tumor heterogeneity of cancer cells.
Being able to detect the smallest signals and trends from the ctDNA biomarker more frequently throughout the cancer management process offers timely insight and may yield information into the most effective treatment regimens tailored to the patient’s specific cancer genomic profile.